Related Experiment Videos
[I. Single nucleotide polymorphism in human genetic analyses]
Kamila Czerska1, Magdalena Nawara, Jerzy Bal
1Pracownia Genetyki Molekularnej, Zaklad Genetyki Medycznej, Instytut Matki i Dziecka, Kasprzaka 17a, 01-211 Warszawa, Poland. czerska@imid.med.pl
Medycyna Wieku Rozwojowego
|June 24, 2004
Summary
Single nucleotide polymorphisms (SNPs) are key genetic markers, representing 90% of human DNA differences. These variations influence disease susceptibility and drug responses, driving pharmacogenetics research.
Area of Science:
- Human Genetics
- Genomics
- Molecular Biology
Context:
- The completion of the Human Genome Project revealed minimal genetic variation among individuals.
- A small fraction of DNA, approximately 0.1%, harbors significant polymorphic changes.
- Single nucleotide polymorphisms (SNPs) constitute the most common type of genetic variation, accounting for about 90% of molecular differences.
Purpose:
- To highlight the significance of SNPs as genetic markers for gene mapping and inheritance studies.
- To explore the role of SNPs in the susceptibility to common complex diseases such as diabetes, cancer, and cardiovascular disorders.
- To introduce SNPs as a central focus in the emerging field of pharmacogenetics.
Summary:
- SNPs are highly frequent single-base DNA alterations, with millions identified across the human genome.
- These genetic variations serve as crucial markers for understanding human heredity and disease predispositions.
- Pharmacogenetics investigates how SNPs contribute to diverse patient responses to medications and their side effects.
Impact:
- SNPs provide insights into the genetic basis of common diseases, enabling personalized risk assessment.
- Understanding SNPs is crucial for advancing pharmacogenetics, aiming to tailor drug therapies to individual genetic profiles.
- Future progress in SNP research promises to significantly enhance pharmacological treatments through genetically informed patient stratification.